Kardiorenal'naya kontseptsiya i sovremennye pozitsii nefroproprotektsii lerkanidipina


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article discusses the problem of nephroprotection in hypertensive patients with renal impairment (cardiorenal syndrome). Pronounced nephroprotective, antihypertensive and lipid-lowering effects of lercanidipine along with its high-safety use have been proven in several clinical studies, that allow to consider this preparation as preferred drug for nephroprotection with blood pressure control in middle-aged and elderly patients with manifestations of advanced atherosclerosis.

Full Text

Restricted Access

About the authors

N. P Lyamina

SBEI HPE "Saratov State Medical University n.a V.I. Razumovsky" of RMPH

Email: lyana_n@mail.ru
MD, Prof., Deputy Director for Science SRI of Cardiology Saratov

A. V Nalivaeva

SBEI HPE "Saratov State Medical University n.a V.I. Razumovsky" of RMPH

Saratov

References

  1. Ronco С, Cullough P., Anker S.D., et al. Cardiorenal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Europ. Heart J. 2010;31:703-11.
  2. Мухин Н.А., Моисеев В.С., Кобалава Ж.Д. и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Терапевт. арх. 2004;(6):39-46.
  3. House A.A., Anand I., Bellomo R. Definition and classification of Cardio-Renal Syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrol. Dial. Transplant. 201;25(5):1416-20.
  4. Heywood J.T. The cardiorenal syndrome: lessons from the ADHERE database and treatment options. Heart. Fail. Rev. 2004;9:195-201.
  5. Forman D.E., Butler J., Wang Y., Abraham W.T., O'Connor C.M., Gottlieb S.S., Loh E., Massie B.M., Rich M.W., Stevenson L.W., Young J.B., Krumholz H.M. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J. Am. Coll. Cardiol. 2004;43:61-7.
  6. Национальные рекомендации: Сердечнососудистый риск и хроническая болезнь почек: стратегии кардионефропротекции. Российский кардиологический журнал. 2014;8(112):7-37.
  7. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Смирнов А.В и члены рабочей группы. СПб., 2012. 51 с.
  8. Смирнов А.В., Добронравов В.А., Каюков И.Г. и др. Эпидемиология и социальноэкономические аспекты хронической болезни почек. Нефрология. 2006;10(1):7-13.
  9. Lao D., Parasher P.S., Cho K.C., Yeghiazarians Y. Atherosclerotic Renal Artery Stenosis -Diagnosis and Treatment. Mayo Clin. Proc. 2011;86(7):649-57.
  10. Рекомендации по лечению артериальной гипертензии ESH/ESC 2013: рабочая группа по лечению артериальной гипертензии Европейского Общества Гипертонии (European society of hypertension, ESH) и Европейского общества кардиологов (European society of Cardiology, ESC). Росс. кардиол. журн. 2014;1(105):7-94.
  11. Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В. Диагностика и лечение артериальной гипертонии. Клинические рекомендации. М., 2013.
  12. Romito R., Pancini M., Francesco P.F., et al. Comparative effect of Lercanidipine Felodipine and Nifedipine GITS on blood pressure and heart rate in patient with mild and moderate arterial hypertension. The Lercanidine in adults (LEAD) study. JCN. 2003;4(5):249-53.
  13. Agrawal R., Marx A., Haller Y. Efficiency and safety of lercanipine versus hydrochlorothiazide as add on to enalapril in diabetic population with uncontrolled hypertension. J. Hypertens. 2006;24(1):185-92.
  14. Zancetti A. Emerging data on calcium channel blockers: the COHORT study. Clin. Cardiol. 2003;26(Supple. 2)II:17-20.
  15. Brown M.J., Palmer C.R., Castaigne A., de Leeuw P.W., Mancia G., Rosenthal T., Ruilope L.M. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366-72.
  16. The ALLHAT officers and coordinators for the ALLHAT Collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-97.
  17. Pepine C.J., Handberg E.M., Cooper-Dehoff R.M., Marks R.G., Kowey P., Messerli F.H., Mancia G., Cangiano J.L., Garcia-Barreto D., Keltai M., Erdine S., Bristol H.A., Kolb H.R., Bakris G.L., Cohen J.D., Parmley W.W. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST), a randomized controlled trial. JAMA. 2003;290:2805-16.
  18. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with valsartan - or amlodipine - based regimens: VALUE, a randomised trial. Lancet. 2004;363:366-72.
  19. Dalhöf B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding ben-drofluazide as required, in Anglo-Scandinavian Cardiac Outcome Trial Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895-906.
  20. Hansson L., Hedner T., Lund-Johansen P., Kjeldsen S.E., Lindholm L.H., Syvertsen J.O., Lanke J., de Faire U., Dahlöf B., Karlberg B.E. Randomised trial of effects of calcium antagonists compared with diuretics and ß-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356:359-65.
  21. Кукес В.Г. Клиническая фармакология. Изд. 4-е. М., 2008.
  22. Borghi C. Lercanidipine in hypertension. Vasc. Health Risk Manag. 2005;1(3):173-82.
  23. Vestra M.D., Pozza G., Mosca A., Grazioli V., Lapolla A., Fioretto P., Crepaldi G. Effect of lercanidipine compared with ramipril on albumin rate in hypertensive Type 2 diabetic with micro-albuminuria: DIAL Study (Diabete, Ipertensione, Albuminuria, Lercanidipina). Diab. Nutr. Metab. 2004;17: 259-66.
  24. Robles N.R., Ocon J., Gomez C.F., Manjon M., Pastor L., Herrera J., Villatoro J., Calls J., Torrijos J., Rodriguez V.I., Rodriguez M.M., Mendez M.L., Morey A., Martinez F.I., Marco J., Liebana A., Rincon B., Tornero F. Lercanidipine in chronic renal failure patients: The ZAFRA Study. Renal Failure. 2005;27:73-80.
  25. Topal C., Erkoc R., Sayarlioglu H. Comparative effects of carvedilol and lercanidipine on ultrafiltration and solute transport in CAPD patients. Renal Failure. 2009;31: 446-51.
  26. Robles N.R., Romero B., de Vinuesa E.G. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Renal Failure. 2010;32:192-97.
  27. Функциональное состояние почек и прогнозирование сердечно-сосудистого риска. Рекомендации комитета экспертов Всероссийского научного общества кардиологов и Научного общества нефрологов России. М., 2009. 20 с.
  28. Peng M.I., Jiang X.J., Dong H., Zou Y.B., Zhang H.M., Wu H.Y., Yang Y. Lercanidipine improve renal function in patients with atherosclerotic renal artery stenosis undergoing renal artery intervention? Curr. Med. Res. Opin. 2015;31(1):177-82.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies